Контактная информация:Вишнёва Елена Александровна, кандидат медицинских наук, заместитель директора НИИ педиатрии по научной работе, заведующая отделом стандартизации и клинической фармакологии, врач аллерголог-иммунолог отделения восстановительного лечения детей с аллергическими болезнями и заболеваниями органов дыхания НИИ педиатрии ННПЦЗД Адрес: 119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (499) Ротавирусная инфекция (РВИ) -антропонозное высококонтагиозное острое инфекционное заболева-ние, характеризующееся преимущественным поражени-ем желудочно-кишечного тракта в виде гастроэнтерита с симптомами диареи и рвоты, развитием общей инток-сикации, дегидратации и нередко наличием респира-торного (катарального) синдрома в начальном периоде болезни. Вирион ротавируса имеет диаметр 65-75 нм и состоит из электронно-плотного центра (сердцевины) и двух белковых оболочек -внутреннего и наружного капсида [1]. Сердцевина содержит внутренние белки и фрагментированную цепь рибонуклеиновой кислоты (РНК), состоящую из 11 сегментов, которые кодируют продукцию белков -6 структурных (Viral Proteins, VP1-VP7: VP1, VP2, VP3, VP4, VP6, VP7) и 5 неструктур-ных (NSP1-NSP5). Основным компонентом внутреннего капсида является структурный белок VP6 (основная группоспецифическая антигенная детерминанта рота-вируса). В зависимости от его строения ротавирусы подразделяют на 7 серологических групп -A, B, C, D, E, F, G. Наружный капсид вириона образован двумя струк-турными белками, к которым в организме человека ХАРАКТЕРИСТИКА ВОЗБУДИТЕЛЯ

During the COVID-19 pandemic, the problem of the population’s adherence to vaccination has become significantly aggravated around the world. This study is aimed at evaluating healthcare workers’ (HCWs) acceptance of COVID-19 vaccination in Russia. A cross-sectional multicenter study was carried out by interviewing HCWs in Russia using an electronic questionnaire and snowball sampling. The analysis included 85,216 questionnaires from 81 out of 85 regions of Russia. Statistical analysis was performed using SPSS v.22. The results indicated that 35.0% (CI 95%, 34.7–35.3) of HCWs were ready to get COVID-19 vaccination. The acceptance level was 42.4% (41.8–42.9) for all physicians and 31.3% (30.9–31.6) for nursing staff. A total of 29.4% (29.1–29.7) of HCWs were willing to recommend COVID-19 vaccination to patients: 38.5% (38.0–39.1) of physicians, and 24.7% (24.4–25.1) of nursing staff. Acceptance of COVID-19 vaccination is higher among HCWs dealing with infectious diseases and involved in vaccination. The low acceptance of HCWs toward vaccination against COVID-19 can be explained by the low level of awareness of HCWs in these issues. Additional educational programs are needed for HCWs, both for physicians and nurses, using all possible forms and methods of education.

No abstract

No abstract

Relevance. Currently, the national calendar of preventive vaccinations does not provide for revaccination against whooping cough in children over the age of 18 months. At the same time, the epidemiological and economic feasibility of revaccination against whooping cough in children aged 6–7 years, as well as adolescents, has been demonstrated in world practice. Aim. Based on a mathematical model, develop a forecast of pertussis morbidity dynamics and assess the potential socio-economic damage under the current and expanded vaccine prophylaxis algorithms.Methods. Mathematical modeling of the potential effect of revaccination against whooping cough in children aged 6–7 years (scenario 1) and at 6–7 years and 14 years (scenario 2) was carried out within the framework of the national calendar of preventive vaccinations. A simulation dynamic mathematical model is constructed that allows predicting the development of the epidemiological process of whooping cough on the basis of the dynamics of the main indicators of its prevalence in the population that developed in previous years. The model took into account dynamic changes in the preventive effectiveness of vaccinations and the potential level of underestimation of morbidity. The obtained arrays of indicators served as the basis for extrapolating trends in morbidity and mortality until 2034.The calculation of epidemiological benefits was carried out in the metrics of prevented loss of years of life under the two scenarios under consideration in comparison with the current vaccination algorithm. The calculation of the economic effect was carried out on the basis of the obtained indicators of epidemiological benefits in the metrics of the monetary equivalent of the average cost of a year of life, taking into account the projected inflation coefficients until 2034.Results. The projected decrease in the number of years of life lived in a state of illness, in comparison with the current situation, will total 44.5 thousand years for the period 2019–2034 under scenario 1 and 66.7 thousand years under scenario 2. The socio-economic damage from prevented cases of the disease, expressed in the monetary equivalent of the average cost of living, will decrease by 28.6% (scenario 1) or 42.0% (scenario 2).Conclusions. A comparison of the received public benefits with the costs of vaccination shows that the expansion of the NCPP with additional revaccinations against whooping cough (at 6–7 years or at 6–7 and at 14 years) is advisable both in epidemiological and economic aspects.